InspireMD's CGuard(TM) Carotid Embolic Prevention System to be Featured at ICCA Stroke 2017 in Moscow, Russia

BOSTON, MA / ACCESSWIRE / March 23, 2017 / InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that its CGuard™ Carotid Embolic Prevention System will be featured at the ICCA Stroke 2017 to be held March 24th-25th at the Vishnevskiy Institute of Surgery of the Ministry of Public Health in Moscow, Russia.

ICCA Stroke is an interdisciplinary and interactive course with leading experts in the field, recorded cases, step by step presentations, debates, and hands-on workshops on catheter-based treatment of acute stroke.

Sessions featuring CGuard™ will include:

Symposium: CGuard Embolic Prevention Stent System - A new paradigm in carotid stenting

Moderator: Horst Sievert, MD / Panagiotis Papanagiotou, MD Panelist: Piotr Musialek, MD / Ivo Petrov, MD / Bernhard Reimers, MD / Sergey V. Volkov, MD / Christian Wissgott, MD

CGuard Embolic Prevention System (EPS) - Routine use in carotid revascularization for stroke prevention: accumulating clinical evidence Speaker: Piotr Musialek, MD, MD, DPhil, FESC, from the Jagiellonian University Department of Cardiac & Vascular Diseases in Krakow, Poland

Clinical results and mechanical properties of a Novel Dual Layer Carotid Stent Speaker: Christian Wissgott, MD, Assistant Director at Westkustenklinikum, Heide, Germany

CGuard challenging cases

Case 1 Speaker: Ivo Petrov, MD

Case 2 Speaker: Sergey V. Volkov, MD

Case 3 Speaker: Bernhard Reimers, MD

Session 5: Case examples of carotid stenting and acute stroke interventions

Moderator: Klaus Mathias, MD / Bagrat Alekyan, MD Panelist: Iris Grunwald, MD / Kenneth Snyder, MD / Alexander Drofa, MD

Complex Carotid Stent Case

Speaker: Piotr Musialek, MD

The CGuard™ Carotid Embolic Prevention System will also be featured at InspireMD's Booth throughout the event.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted on the NYSE MKT under the ticker symbol NSPR.WS.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: craigs@inspiremd.com

Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: NSPR@crescendo-ir.com

SOURCE: InspireMD, Inc.